Earnings release
Page 1
ASX ANNOUNCEMENT 26 October 2026 Quarterly Activities & Appendix 4C September 2026 • IQVIA data shows Activated Probiotics gained market share nationally and in every region, with Biome Daily extending its lead as the number one probiotic product in Australian pharmacy by both units and dollar value1 • Record quarter of wholesaler sell-through of Activated Probiotics to Australian pharmacy • Onshore manufacturing with Specialty Probiotics Australia (SPA) under way, with Australian-made Activated Probiotics expected on pharmacy shelves from November 2026 • Exclusive cross-border e-commerce (CBEC) distribution heads of agreement signed with H&S Global for the Activated Probiotics range in mainland China (announced 27 August 2026), with launch planned within FY27 • Recruitment for the BMB18 human clinical trial under way in Melbourne and Athens, with 48 participants (20%) recruited to date • Biome Daily 60 and Biome Daily Kids 60 packs launching in Q2 FY27, in response to customer demand for a larger pack size • Cash of $3.4m at 30 September 2026, down $170k on Q4 FY26, with total available funding of $6.5m and drawn debt unchanged at $1.9m • Cash receipts from customers of $6.5m, up 10% on Q4 FY26 • Net operating cash inflow of $100k for Q1 FY27, following a second consecutive full-year net profit in FY26 1 IQVIA™ Sell Out Service, VITAMINS & SUPPLEMENTS category, CHC3=PROBIOTICS, Australia Pharmacy, Total Value and Unit, 52 Weeks W/E 3 October 2026.
Page 2
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the Company’) is pleased to provide its Appendix 4C and Activity Report for the quarter ended 30 September 2026 (“Q1 FY27”). Q1 FY27 was a quarter of significant operational progress for Biome, with onshore manufacturing under way, heads of agreement signed for cross-border e-commerce entry into China, and record demand for Activated Probiotics through pharmacy. The most recent IQVIA data confirms Biome Daily has extended its lead as the number one probiotic product in Australian pharmacy, by both units and dollar value (52 weeks to 3 October 2026). Q1 FY27 was Biome’s highest quarter of wholesaler sell-through to pharmacy on record, and IQVIA shows consumer sales of Activated Probiotics through pharmacy also reached their highest quarter, increasing both same-store sales and market share nationally and in every region. Production with SPA has been under way since September, with Australian-made Activated Probiotics expected to reach pharmacy shelves from November 2026 (Q2 FY27). Onshore manufacturing is expected to deliver a structural improvement in cost of goods sold and reduce working capital requirements over time, while removing Biome’s exposure to currency movements, international freight volatility and offshore supply chain disruption. During the quarter, Biome, through its wholly owned subsidiary Biome Australia Trading Pty Ltd, entered into a heads of agreement with H&S Global (announced 27 August 2026) for the exclusive distribution of Activated Probiotics in mainland China through cross-border e-commerce, under a three-year initial term. Exclusivity applies for the first year, with continuation into years two and three subject to purchase targets agreed between the parties. The heads of agreement is binding in respect of exclusivity and certain other matters, and completion is subject to execution of a master distribution agreement. The Company continues to finalise set-up and launch plans with H&S Global, and negotiation of the master distribution agreement, on execution of which volumes, targets and the launch date will be confirmed, is progressing. Launch remains planned within FY27. As announced on 9 September 2026, Biome Daily 60 and Biome Daily Kids 60 packs will launch in Q2 FY27. The new pack sizes respond to strong customer demand for a larger pack, particularly from parents,
Page 3
and spread volume across the two highest-selling products in the range. Recruitment for the multi-centre BMB18 human clinical trial is under way in Melbourne and Athens, with 48 participants (20%) recruited to date. Biome Australia Founder and Managing Director, Blair Vega Norfolk, said: “We back our products with clinical evidence. The Activated Probiotics range is supported by more than 30 randomised, double-blind, placebo-controlled trials. It is practitioner-recommended, used every day by leading health professionals and trusted by their patients. That is what is driving Biome Daily extending its lead as the number one probiotic in Australian pharmacy. We have built that position on evidence and practitioner recommendation, not marketing spend. It shows our evidence-led strategy is the right one, and it is what consumers are asking for. This quarter we started making Activated Probiotics in Australia, signed with H&S Global for China and continued our BMB18 trial in Melbourne and Athens. BMB18 is our own strain, and we are putting it through the same level of clinical testing as the rest of the range. We have now delivered two consecutive years of net profit. We are using that to invest in our science, our manufacturing and new markets. As we move through the final year of Vision 27, we are planning the next phase of growth.”
Page 4
Quarterly Financial Update Biome reported its second consecutive full-year net profit in FY26 and generated a net operating cash inflow of $100k in Q1 FY27, achieved during a period of significant operational change. Cash receipts from customers were $6.5m, up $0.6m (10%) on Q4 FY26 ($5.9m), reflecting continued sales growth in Australia and in Biome’s international markets. The Company closed the quarter with cash of $3.4m and total available funding of $6.5m, comprising cash and unused NAB facilities. Drawn debt was unchanged from 30 June 2026 at $1.9m, against total facilities of $5.0m. The Company maintained disciplined control of working capital while running offshore and onshore production in parallel, managing a step-change in domestic sales volumes and preparing for entry into the China market. Payments for product manufacturing and operating costs were $2.9m, 17% lower than pcp ($3.5m). On a cash basis for the quarter, direct brand marketing investment totalled $480k. As a function of cash receipts from customers, direct brand marketing represented approximately 7.4% for Q1 FY27. Staff costs on a cash basis were $2.6m for the quarter. From Q1 FY27, the Company reports payments to employees in research and development roles within staff costs (item 1.2(e) of the Appendix 4C), rather than within research and development (item 1.2(a)) as in prior quarters. The Company considers this classification better reflects the nature-based presentation used in the Company’s statutory financial statements. Payments for research and development now comprise external costs only. Q1 FY27 cash outflows attributable to staff costs include the settlement of annual bonuses and the LTI of the former CFO, totalling $416k. Investing activities in the quarter included $179k in payments for intellectual property, including costs associated with the BMB18 patent application and clinical trial, and $3k in payments for property, plant and equipment. Financing activities in the quarter included $33k in proceeds from the issue of equity securities, being the sale of shares that transferred to the Company following the forfeiture of unvested shares under the
Page 5
Company’s Loan Funded Share Plan, and $106k in payments for lease liabilities. Consistent with the approach adopted from Q3 FY26, the Company reports operational metrics as its primary quarterly indicators, with full financial results disclosed at the half-year and full-year. The amount paid to Directors of the Company during the quarter was $300,211 in fees, salaries, short-term incentive payments and superannuation payments, as follows: ● Executive Director $237,440 ● Non-Executive Directors $62,771 –ENDS– Approved for release by the Biome Australia board of directors. Investor Hub Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at https://investorhub.biomeaustralia.com/. About Biome Australia Limited Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all. Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®. Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics and Activated Therapeutics help support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner and pharmacy distribution, Biome
Page 6
is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns. For more information visit: www.biomeaustralia.com Investor Relations Lauren Dwyer, Chief Financial Officer corporate@biomeaustralia.com (03) 9017 5800 Media enquiries media@activated.co Forward Looking Statements This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements. The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of
Page 7
a change in expectations or assumptions, new information, future events or results or otherwise. To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.
Page 8
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity BIOME AUSTRALIA LIMITED (BIO) ABN Quarter ended (“current quarter”) 51 627 364 014 30 September 2026 Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 1. Cash flows from operating activities 1.1 Receipts from customers 6,518 6,518 1.2 Payments for (a) research and development (43) (43) (b) product manufacturing and operating costs (2,896) (2,896) (c) advertising and marketing (480) (480) (d) leased assets - - (e) staff costs (2,580) (2,580) (f) administration and corporate costs (446) (446) 1.3 Dividends received (see note 3) - - 1.4 Interest received - - 1.5 Interest and other costs of finance paid (29) (29) 1.6 Income taxes and FBT paid (4) (4)
Page 9
Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 1.7 Government grants and tax incentives 60 60 1.8 Other (provide details if material) - - 1.9 Net cash from / (used in) operating activities 100 100 2. Cash flows from investing activities 2.1 Payments to acquire or for: (a) entities - - (b) businesses - - (c) property, plant and equipment (3) (3) (d) investments - - (e) intellectual property (179) (179) (f) other non-current assets - - 2.2 Proceeds from disposal of: (a) entities - - (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received (see note 3) - -
Page 10
Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 2.5 Other (provide details if material) - - 2.6 Net cash from / (used in) investing activities (182) (182) 3. Cash flows from financing activities 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 33 33 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - - 3.4 Transaction costs related to issues of equity securities or convertible debt securities - - 3.5 Payments for lease liabilities (106) (106) 3.6 Proceeds from/ (repayment of) borrowings - - 3.7 Transaction costs related to loans and borrowings - - 3.8 Dividends paid - - 3.9 Other (provide details if relevant) - - 3.10 Net cash from / (used in) financing activities (73) (73)
Page 11
Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 4. Net increase / (decrease) in cash and cash equivalents for the period 4.1 Cash and cash equivalents at beginning of period 3,552 3,552 4.2 Net cash from / (used in) operating activities (item 1.9 above) 100 100 4.3 Net cash from / (used in) investing activities (item 2.6 above) (182) (182) 4.4 Net cash from / (used in) financing activities (item 3.10 above) (73) (73) 4.5 Effect of movement in exchange rates on cash held (15) (15) 4.6 Cash and cash equivalents at end of period 3,382 3,382 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts Current quarter $A’000 Previous quarter $A’000 5.1 Bank balances 3,382 3,552 5.2 Call deposits - - 5.3 Bank overdrafts - - 5.4 Other (provide details) - - 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 3,382 3,552
Page 12
6. Payments to related parties of the entity and their associates Current quarter $A'000 6.1 Aggregate amount of payments to related parties and their associates included in item 1 300 6.2 Aggregate amount of payments to related parties and their associates included in item 2 Nil Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments. The amount paid to Directors of the Company during the quarter was $300,211 in fees, salaries, short-term incentive payments and superannuation payments, as follows: ● Executive Director $237,440 ● Non-Executive Directors $62,771 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $A’000 Amount drawn at quarter end $A’000 7.1 Loan facilities 5,000 1,900 7.2 Credit standby arrangements Nil n/a 7.3 Other (please specify) Nil n/a 7.4 Total financing facilities 5,000 1,900 7.5 Unused financing facilities available at quarter end 3,100
Page 13
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. Biome Australia Trading Pty Ltd ("Biome Trading") a wholly owned subsidiary of the Company has entered into a $5.0m secured debt facility ("Facility") with NAB for working capital purposes to fund future growth, comprising a $3.5m NAB Invoice Finance Facility and a $1.5m NAB Trade Finance Facility. $3.5m NAB Invoice Finance Facility This facility provides invoice funding for Biome's Australian accounts receivables. The current interest rate of the facility is 7.75% p.a. The facility carries an application fee of $12,250 plus a monthly facility fee of $1,700. This is an ongoing facility with no set expiry date. $1.5m NAB Trade Finance Facility The current interest rate of the facility is 7.53% p.a. The facility carries an application fee of $5,250 plus a facility fee of 1.3% p.a. This facility was set to expire on 27 February 2026 and was extended by a year, to 27 February 2027. The facility is secured by a General Security Agreement over the whole of Biome Trading's assets, a First ranking priority charge over the whole of Biome Trading's receivables (debtor) book and a Deed of Guarantee and Indemnity from the Company, supported by a General Security Agreement over the whole of the assets of the Company.
Page 14
8. Estimated cash available for future operating activities $A’000 8.1 Net cash from / (used in) operating activities (item 1.9) 100 8.2 Cash and cash equivalents at quarter end (item 4.6) 3,382 8.3 Unused finance facilities available at quarter end (item 7.5) 3,100 8.4 Total available funding (item 8.2 + item 8.3) 6,482 8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) N/A Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5. 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: n/a 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: n/a 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: n/a Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Page 15
Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 26 October 2026 Authorised by: The Board (Name of body or officer authorising release – see note 4) Notes 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so. 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report. 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity. 4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”. 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.